BioMed Research International / 2016 / Article / Tab 3

Review Article

Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Table 3

Selective studies evaluating therapy related risk of lymphoma in RA patients.

Author YearTherapyDiseaseSample populationMeasure of riskComparison groupRisk

Wolfe and Michaud [48]2007Inf., Etan., and Ana.RA19,591ORAll RA patients not on anti-TNF therapy1.0 (0.6, 1.8)
Anti-TNF therapy plus MTXRAORMTX therapy alone1.1 (0.6, 2.0)

Geborek et al. [49]2005Inf. and Etan.RA757 (anti-TNF group) versus 800 (conventional treatment)AHRAnti-TNF alpha naive RA patients5.0 (0.9, 27.9)

Askling et al. [50]2005Inf., Etan., and Ana.RA4160ARRAll RA patients/all treatments1.1 (0.6, 2.1)

Setoguchi et al. [51]2006Inf., Etan., and Ana.RA1152 biologic users versus 7306 MTX usersAHRRA patients with MTX use only1.11 (0.51, 2.37)

Askling et al. [18] 2009Inf., Etan., and Ana.RA6604ARRAnti-TNF alpha naive RA patients1.35 (0.82, 2.11)

Wolfe and Michaud [52] 2004MTXRA18,572SIRGeneral population1.7 (95% CI 0.9–3.2)
Infliximab and etanerceptSIR2.9 (95% CI 1.7–4.9)

Buchbinder et al. [53]2008MTXRA459SIRGeneral population5.1 (2.2–10.0)

Inf.: infliximab; Etan.: etanercept; Ana.: anakinra; RA: rheumatoid arthritis; MTX: methotrexate; ARR: adjusted relative risk; AOR: adjusted odds ratio; AHR: adjusted hazard ratio; SIR: standardized incidence ratio.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.